Jyoti D Patel

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma
    Jyoti D Patel
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Lung Cancer 6:S43-7. 2004
  2. ncbi Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies
    Jyoti D Patel
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Curr Opin Oncol 18:609-14. 2006
  3. ncbi Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
    Jyoti D Patel
    Feinberg School of Medicine, Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    J Clin Oncol 27:3284-9. 2009
  4. ncbi Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance
    Jyoti D Patel
    Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Lung Cancer 10:252-6. 2009
  5. ncbi Lung cancer: a biologically different disease in women?
    Jyoti D Patel
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Womens Health (Lond Engl) 5:685-91. 2009
  6. ncbi Lung cancer in women
    Jyoti D Patel
    Division of Hematology Oncology, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 23:3212-8. 2005
  7. ncbi Induction chemotherapy for resectable non-small-cell lung cancer
    Jyoti D Patel
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 18:1591-602; discussion 1602-3, 1606, 1611-2. 2004
  8. ncbi Lung cancer in US women: a contemporary epidemic
    Jyoti D Patel
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, and the Robert H Lurie Comprehensive Cancer Center, Chicago, Ill 60611, USA
    JAMA 291:1763-8. 2004
  9. ncbi Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
  10. ncbi The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Mary J Fidler
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 14:2088-94. 2008

Detail Information

Publications19

  1. ncbi Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma
    Jyoti D Patel
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Lung Cancer 6:S43-7. 2004
    ..Furthermore, recent insights into mechanisms of drug sensitivity should impact future clinical trial design...
  2. ncbi Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies
    Jyoti D Patel
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Curr Opin Oncol 18:609-14. 2006
    ..Recent findings regarding clinical activity as well as markers associated with sensitivity to these agents will be reviewed...
  3. ncbi Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
    Jyoti D Patel
    Feinberg School of Medicine, Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    J Clin Oncol 27:3284-9. 2009
    ....
  4. ncbi Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance
    Jyoti D Patel
    Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Lung Cancer 10:252-6. 2009
    ....
  5. ncbi Lung cancer: a biologically different disease in women?
    Jyoti D Patel
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Womens Health (Lond Engl) 5:685-91. 2009
    ..A more thorough understanding of the biologically different aspects of lung cancer across different populations may lead to innovations in prevention and treatment...
  6. ncbi Lung cancer in women
    Jyoti D Patel
    Division of Hematology Oncology, Northwestern University, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 23:3212-8. 2005
    ..Lung cancer patients have few therapeutic options. A more thorough understanding of the heterogeneity of lung cancer across populations may lead to innovations in treatment and prevention strategies...
  7. ncbi Induction chemotherapy for resectable non-small-cell lung cancer
    Jyoti D Patel
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 18:1591-602; discussion 1602-3, 1606, 1611-2. 2004
    ..Randomized trials are under way to better define the role of induction therapy in the multimodality treatment of NSCLC...
  8. ncbi Lung cancer in US women: a contemporary epidemic
    Jyoti D Patel
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, and the Robert H Lurie Comprehensive Cancer Center, Chicago, Ill 60611, USA
    JAMA 291:1763-8. 2004
    ..Finally, disseminating information about this epidemic may prevent a similar epidemic in other parts of the world where women are just now becoming addicted to tobacco...
  9. ncbi Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
    ..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
  10. ncbi The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Mary J Fidler
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 14:2088-94. 2008
    ..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC...
  11. ncbi Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go
    Jyoti D Patel
    Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Crit Rev Oncol Hematol 50:175-86. 2004
    ..The goal of ongoing and future investigation is to identify which patients may benefit from this new therapeutic approach...
  12. ncbi Pemetrexed: a novel antifolate agent enters clinical practice
    Victoria Kut
    Department of Medicine, Division of Hematology/Oncology, The Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 4:511-22. 2004
    ..Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer...
  13. ncbi Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at
    Narissa J Nonzee
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 113:1446-52. 2008
    ..Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications...
  14. ncbi Improving health-related quality of life in non-small-cell lung cancer with current treatment options
    David F Cella
    Evanston Northwestern Healthcare, Evanston, IL, USA
    Clin Lung Cancer 9:206-12. 2008
    ..This article discusses current approaches to measuring health-related QOL. This discussion is followed by a brief review of some of the current treatment options for patients with NSCLC and their effect on health-related QOL...
  15. ncbi Sex differences in susceptibility to carcinogens
    Kavitha Ramchandran
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 36:516-23. 2009
    ..These hypotheses will be explored in depth in this article...
  16. ncbi Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer
    Peter Kulesza
    Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Am J Clin Pathol 136:228-38. 2011
    ..The role of pathologists in guiding treatment decisions will increase because molecular profiling, together with pathologic and histologic analysis, represents the future of personalizing medicine for patients with NSCLC...
  17. ncbi Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report
    Ryan J Halpin
    Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Surg Neurol 63:469-74; discussion 474-5. 2005
    ..In properly selected patients, RFA may also increase the duration of local spinal stabilization afforded by the vertebroplasty alone. Long-term studies are warranted to assess the efficacy and durability of this unique approach...
  18. ncbi Targeting lethal minimal residual disease in small cell lung cancer
    Jyoti D Patel
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 30:79-85. 2003
    ..This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy...
  19. ncbi Non-small cell lung cancer
    David S Ettinger
    J Natl Compr Canc Netw 6:228-69. 2008